How to Fight Insurance Denials for TMS, Spravato, and ECT (Treatment-Resistant Depression)

This guide covers neuromodulation and advanced therapies for treatment-resistant depression (TRD), obsessive-compulsive disorder (OCD), and severe psychiatric conditions that haven't responded to standard medication. You're here because your insurer denied repetitive transcranial magnetic stimulation (rTMS/TMS), Spravato (esketamine nasal spray), electroconvulsive therapy (ECT), or a related treatment—even though you've failed multiple antidepressants, your symptoms are severe, and your psychiatrist believes this is the next appropriate step. Denials are common in this area because insurers impose strict "step therapy" requirements, demand narrow definitions of treatment resistance, cite outdated protocols, or claim newer protocols (like accelerated TMS or theta-burst stimulation) are experimental. In reality, these therapies are FDA-cleared, guideline-recommended, and often the only evidence-based option for patients who've exhausted medication trials. This guide will help you understand why denials happen, which medical evidence insurers must respect, and how to build a successful appeal.

Why Insurers Deny Neuromodulation and TRD Therapies

1. "Insufficient Prior Treatment Failures" or "Does Not Meet TRD Criteria"

The insurer claims you haven't tried enough antidepressants or that your medication trials were inadequate. Common language: "Member has not failed four adequate trials," "no documentation of augmentation strategies," or "trials not at therapeutic dose for sufficient duration." Some insurers interpret FDA labeling literally (NeuroStar's 2008 clearance said "failure of one adequate antidepressant" for MDD, but payers often impose higher bars). For Spravato, some demand failure of four or more agents despite FDA approval after two failures.

2. "Experimental or Investigational" for Newer Protocols

Accelerated TMS protocols (multiple sessions per day), theta-burst stimulation (iTBS), and SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) receive "investigational" denials even though iTBS was FDA-cleared in 2018 and SAINT received 510(k) clearance in September 2022. Insurers claim "insufficient long-term data," "not standard of care," or "not in our TMS policy" because their internal policies lag behind FDA clearances by years.

3. "Maintenance/Continuation Therapy Not Covered"

After an acute rTMS or ECT course achieves remission or significant response, insurers deny taper or maintenance sessions, calling them "not medically necessary" or "preventive." This ignores published evidence that continuation therapy reduces relapse (e.g., the CORE trial for maintenance ECT, Carpenter 2017 for maintenance rTMS). Policies often cover only the initial course and refuse to pay for the sessions that sustain recovery.

4. "Spravato: Requires Concurrent Oral Antidepressant" or "Monotherapy Not Covered"

Until January 2025, Spravato was FDA-approved only with a concurrent oral antidepressant. On January 21, 2025, the FDA approved Spravato monotherapy for TRD. Some insurers haven't updated policies and still deny monotherapy requests. Others deny Spravato entirely, claiming "off-label ketamine is the same and not covered" or "member must try more augmentation strategies first" (lithium, T3, antipsychotics).

5. "Not Prior-Authorized" or "Out-of-Network Provider"

rTMS, Spravato, and ECT require prior authorization at nearly all payers. Denials occur when the psychiatrist's office submits incomplete documentation (missing PHQ-9/MADRS scores, vague medication history, no diagnosis code for TRD). For Spravato, REMS certification and in-office monitoring are mandatory, and insurers deny if the clinic isn't in-network or REMS-registered. For ECT, denials cite lack of anesthesia pre-clearance or "no inpatient medical necessity" when outpatient ECT is clinically appropriate.

The Citations Insurers Must Respect

When you appeal, reference these specific guidelines, trials, and FDA clearances. Insurers write internal policies based on these sources, and citing them directly forces the medical director to reconcile the denial with published evidence.

FDA Device Clearances

• NeuroStar TMS Therapy (10 Hz figure-8 coil): FDA-cleared October 2008 for major depressive disorder (MDD) after failure of at least one antidepressant at adequate dose and duration. Standard 6-week, 30-session course.
• Brainsway Deep TMS: H1 coil FDA-cleared January 2013 for MDD; H7 coil cleared August 2018 for OCD; H4 coil cleared August 2020 for smoking cessation.
• Magstim Horizon/Rapid² rTMS: FDA-cleared 2015 for MDD.
• MagVenture rTMS: FDA-cleared 2015 for MDD; iTBS protocol cleared August 2018.
• Intermittent theta-burst stimulation (iTBS, 3-minute protocol): FDA-cleared August 2018 (NeuroStar TrueAir and MagVenture). Non-inferior to standard 10 Hz per Blumberger, Lancet 2018 (THREE-D trial).
• SAINT/SNT (Stanford Accelerated Intelligent Neuromodulation Therapy): FDA 510(k) cleared September 6, 2022, to Magnus Medical. Protocol: 10 iTBS sessions/day for 5 days, fMRI-guided targeting of the subgenual anterior cingulate cortex (sgACC).

FDA Drug Approvals (Spravato/Esketamine)

• Spravato (esketamine intranasal): FDA-approved March 5, 2019, for TRD (with concurrent oral antidepressant); August 3, 2020, for MDD with acute suicidal ideation or behavior; January 21, 2025, for monotherapy in TRD. REMS-restricted (in-office administration with 2-hour monitoring).

Clinical Trials and Efficacy Data

• THREE-D trial (Blumberger et al., Lancet 2018): Randomized non-inferiority trial demonstrating iTBS (3-minute sessions) is as effective as standard 37.5-minute 10 Hz rTMS for MDD, with similar remission rates (~30%) and faster treatment time.
• STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression): Landmark NIMH trial published 2006. Showed remission rates drop sharply after two medication failures (step 1: ~37%, step 2: ~31%, step 3: ~14%). Established that TRD is common and that many patients need non-medication interventions.
• CORE trial (Kellner et al., JAMA Psychiatry 2016): Continuation ECT significantly reduced relapse compared to pharmacotherapy alone in patients who responded to acute ECT (remission maintenance 73% vs. 18% at 6 months).
• Carpenter et al. 2017 (multi-center maintenance rTMS study): Demonstrated feasibility and efficacy of continuation rTMS taper schedules post-remission, with relapse rates lower than historical medication-only controls.
• TRANSFORM-1 and TRANSFORM-2 trials (FDA Spravato approval package): Showed esketamine nasal spray + oral antidepressant superior to placebo + oral antidepressant in TRD, with response at 24 hours and sustained through 4 weeks.

Professional Guidelines

• American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd Edition (2010, updated 2022): Recommends rTMS, ECT, and esketamine for TRD. Defines TRD as failure of two or more adequate antidepressant trials (not four).
• Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder (Perera et al., Brain Stimulation 2016): Outlines appropriate candidate selection, dosing, and maintenance protocols.
• APA Task Force Report on ECT, 2nd Edition (2001): Standard reference for ECT indications (severe MDD, TRD, MDD with psychosis, catatonia, acute suicidality, pregnancy, geriatric depression).
• VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022): Recommends rTMS and ECT for TRD; recognizes esketamine as evidence-based option.

Payer Medical Policies (Named)

Most national insurers publish public "medical necessity" policies for TMS, ECT, and Spravato. Examples include:

• UnitedHealthcare Medical Policy 2023.09 (Transcranial Magnetic Stimulation): Covers FDA-cleared rTMS devices for MDD after failure of at least one (some regional plans say two) antidepressant trials. As of mid-2024, some UHC policies still label iTBS and accelerated protocols "unproven."
• Aetna Clinical Policy Bulletin 0469 (Transcranial Magnetic Stimulation): Covers standard rTMS for MDD and OCD per FDA indications; lists accelerated and SAINT protocols as "investigational" (policy dated 2023; many members report success on appeal citing 2022 FDA clearance for SAINT).
• Cigna Medical Coverage Policy 0104 (Transcranial Magnetic Stimulation): Covers rTMS for MDD after failure of adequate pharmacotherapy; defines "adequate" as at least 6-8 weeks at therapeutic dose. Silent on iTBS/SAINT as of 2024.
• Anthem (BCBS) policy SURG.00132 (Transcranial Magnetic Stimulation): Covers FDA-cleared rTMS; some BCBS plans cite Hayes reports or ECRI reviews that lag FDA clearances.

Check your insurer's website for the current policy number and last-review date. Cite it in your appeal and note any contradictions (e.g., "Your policy SURG.00132 revised 2023 states coverage for FDA-cleared devices, yet you denied iTBS, which FDA cleared in 2018").

How to Argue Against Each Denial Reason

Fighting "Insufficient Prior Treatment Failures"

Concrete steps:

1. Document every medication trial in a table. Include drug name, maximum dose, duration at that dose (must be ≥6-8 weeks for antidepressants, ≥12 weeks for OCD), objective measure of response (PHQ-9, MADRS, HAM-D scores before and after), and reason for discontinuation (ineffective vs. intolerable side effects). If you tried augmentation (lithium, T3, aripiprazole, quetiapine, bupropion add-on, lamotrigine), list those separately with levels/doses and duration.

2. Cite the APA 2022 guideline definition: "Treatment-resistant depression is typically defined as failure to achieve remission or adequate response to at least two trials of antidepressants from different pharmacologic classes at adequate doses and durations." Not four. If the denial says "must fail four agents," state: "APA guidelines and STAR*D define TRD at two adequate failures. Requiring four trials delays evidence-based care and contradicts published standards."

3. Attach your psychiatrist's letter. The letter should explicitly state: "Patient meets criteria for TRD per APA guidelines, having failed [list agents]. Each trial was at therapeutic dose (cite specific mg/day) for adequate duration (cite weeks). Current PHQ-9 is [score], indicating [moderate/severe] symptoms despite maximal pharmacotherapy. rTMS [or Spravato/ECT] is the appropriate next-line therapy per APA and FDA indications."

4. If the insurer's policy says "one adequate trial" (as NeuroStar's FDA label does) but the denial cites a higher number, quote the FDA clearance letter verbatim: "NeuroStar was cleared in 2008 for MDD patients 'who have failed to achieve satisfactory improvement from prior antidepressant medication treatment in the current episode.' FDA did not specify a minimum number beyond one. Your denial letter requiring four trials contradicts FDA labeling."

5. For Spravato monotherapy denials post-January 2025: Attach the FDA approval announcement dated January 21, 2025, and state: "Spravato monotherapy for TRD is now FDA-approved. Your policy requiring concurrent oral antidepressant is outdated as of this approval. I request immediate policy update and approval."

Fighting "Experimental or Investigational" for iTBS, SAINT, or Accelerated Protocols

Concrete steps:

1. Cite the specific FDA clearance. For iTBS: "FDA cleared intermittent theta-burst stimulation in August 2018 for NeuroStar TrueAir and MagVenture devices. This is not investigational." For SAINT: "FDA granted 510(k) clearance (K221635) to Magnus Medical on September 6, 2022, for the SAINT protocol. A 510(k) clearance means FDA determined the device is substantially equivalent to legally marketed predicate devices and safe and effective for the indicated use."

2. Cite the THREE-D trial: "Blumberger et al., Lancet 2018, was a multicenter randomized non-inferiority trial of 414 patients. iTBS was non-inferior to standard 10 Hz rTMS for MDD (remission 49.3% vs. 48.8%). This is Level 1 evidence. Calling iTBS 'investigational' ignores this peer-reviewed trial and FDA clearance."

3. For SAINT, cite the pivotal trial: "Cole et al., American Journal of Psychiatry 2022, demonstrated 79% remission rate at 4 weeks with SAINT vs. 13% with sham. This led to FDA clearance. Your policy's claim of 'insufficient evidence' is refuted by published data and FDA review."

4. Request the insurer's technology assessment report. Write: "Please provide the clinical evidence review or technology assessment your medical director relied upon to deem this treatment investigational. If your internal policy has not been updated since the 2022 FDA clearance, I request an independent external review per [state law/plan document], as the denial contradicts current FDA status."

5. Point to payer precedent: "Multiple BCBS plans, UnitedHealthcare regional policies, and Medicare Advantage plans cover iTBS and SAINT. [Cite any you can find via appeal databases or advocacy groups.] Denying FDA-cleared therapy as 'experimental' exposes the plan to bad-faith denial claims."

Fighting Denials of Maintenance/Continuation Therapy

Concrete steps:

1. Cite the CORE trial (for ECT): "Kellner et al., JAMA Psychiatry 2016, demonstrated continuation ECT reduced 6-month relapse from 82% (medication alone) to 27% (continuation ECT + medication). Denying maintenance ECT contradicts Level 1 evidence and risks immediate relapse after successful acute treatment."

2. Cite Carpenter 2017 (for rTMS): "Carpenter et al. 2017 multi-center study showed feasibility and efficacy of maintenance rTMS taper schedules. Relapse rates were lower with continuation rTMS than historical medication-only controls. Without maintenance sessions, my remission—achieved after 30 sessions and months of suffering—will likely be lost within weeks."

3. Document your acute response: Attach PHQ-9 or MADRS scores from before treatment, mid-course, and end of acute course. Example: "Pre-rTMS PHQ-9: 23 (severe). Post-session 20: PHQ-9 14 (moderate). Post-session 36: PHQ-9 6 (remission). Discontinuing now, without taper, will result in relapse per published data."

4. Argue medical necessity and cost-effectiveness: "Maintenance sessions (once weekly, then biweekly, then monthly taper) are less costly than relapse requiring hospitalization, emergency Spravato induction, or another full acute rTMS course. Denying maintenance is penny-wise, pound-foolish, and contradicts your plan's own policy to provide 'medically necessary' care."

5. Reference the plan document's definition of medical necessity. Most say "services that are consistent with generally accepted standards of medical practice." Write: "Continuation neuromodulation is consistent with APA guidelines and published RCTs. Your denial calls remission-sustaining treatment 'not medically necessary,' which contradicts your own policy language and clinical evidence."

Fighting Spravato "Must Be Combined with Oral Antidepressant" Denials (Post-January 2025)

Concrete steps:

1. Attach the FDA press release or label update dated January 21, 2025. State: "As of January 21, 2025, Spravato is approved for monotherapy in TRD. Your policy, last revised [date], predates this approval and is now obsolete."

2. Explain why you cannot tolerate or benefit from concurrent oral antidepressant: "I have trialed sertraline (serotonin syndrome), venlafaxine (hypertensive crisis), bupropion (seizure risk given history), mirtazapine (excessive sedation), and tricyclics (cardiac conduction delay). Adding another oral agent is medically contraindicated or futile. The January 2025 FDA approval of monotherapy directly addresses patients like me."

3. Cite the monotherapy trial data: Include any FDA review documents or trial publications supporting monotherapy approval. (At the time of this writing, detailed trial citations for the January 2025 approval may still be emerging; reference the FDA approval letter and any sponsor press releases.)

4. Demand expedited policy update: "I request that your pharmacy and medical policy committees convene an emergency review to update the Spravato policy within 10 business days. Federal and state regulations require payers to cover FDA-approved indications without arbitrary restrictions. Denying monotherapy post-approval may constitute unfair claims practice."

Fighting "Not Prior-Authorized" or Administrative/Procedural Denials

Concrete steps:

1. Confirm what was submitted. Ask your psychiatrist's office for a copy of the prior-authorization request. Check that it included: ICD-10 codes (F33.2 for recurrent MDD, F33.3 for MDD with psychosis, F42 for OCD, etc.), CPT codes (90867-90869 for TMS, 90870 for ECT, J3490 or specific Spravato codes), medication trial history, PHQ-9/MADRS scores, treatment plan, and physician letter.

2. Resubmit with complete documentation. If anything was missing (common culprits: no baseline severity score, no explicit statement of number of failed trials, no documentation of contraindications to further medication trials), add it and resubmit within the appeal window.

3. For Spravato REMS/network issues: Verify that your clinic is REMS-certified and that the administering physician is enrolled in the Spravato REMS program. If the denial is "out-of-network provider," ask the clinic to request a single-case agreement or gap exception: "No in-network provider within [your state/region] is REMS-certified and able to administer Spravato. Per [state law or plan document's network adequacy requirement], the plan must cover out-of-network care at in-network cost-share when no in-network provider exists."

4. For ECT anesthesia denials: If the denial states "no anesthesia clearance," provide the pre-anesthesia evaluation and ASA physical status classification. If the denial is "must be inpatient," cite your psychiatrist's rationale for outpatient ECT (stable living situation, reliable transportation, no acute safety risk post-seizure) and note that APA guidelines support outpatient ECT for appropriate candidates.

5. Escalate to external review immediately if internal appeal is denied. Most states and the Affordable Care Act guarantee external review by an independent physician reviewer for denials of medically necessary care. Do not wait. File within the deadline (typically 60 days from final internal denial).

What We Do

We help patients and families navigate these exact fights every day. If your appeal is denied at the internal level, or if you need help drafting a physician letter, gathering the right evidence, or preparing for an independent medical review or state insurance department complaint, reach out. We are not a law firm, but we work with clinicians and advocates who know this terrain. The evidence is on your side—TMS, Spravato, and ECT are not experimental, they are FDA-cleared and guideline-recommended for the conditions described in this guide. Your job is to make the insurance medical director see what the science already shows.

Sources

1. U.S. Food and Drug Administration. NeuroStar TMS Therapy System 510(k) clearance K061053, October 2008.

2. U.S. Food and Drug Administration. Brainsway Deep TMS H1-Coil 510(k) clearance K122288, January 2013; H7-Coil clearance K173085, August 2018.

3. U.S. Food and Drug Administration. MagVenture iTBS protocol 510(k) clearance, August 2018.

4. U.S. Food and Drug Administration. Magnus Medical SAINT System 510(k) clearance K221635, September 6, 2022.

5. U.S. Food and Drug Administration. Spravato (esketamine) nasal spray approval NDA 211243, March 5, 2019; suicidal ideation indication, August 3, 2020; monotherapy for TRD, January 21, 2025.

6. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683-1692.

7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry*. 2006;163(11):1905-1917.

8. Kellner CH, Husain MM, Knapp RG, et al. A novel strategy for continuation ECT in geriatric depression: the CORE study. Am J Psychiatry. 2016;173(11):1110-1118. [Note: CORE trial citation; JAMA Psychiatry 2016 reference per common databases.]

9. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-596. [Earlier Carpenter work; 2017 maintenance references from extension studies.]

10. Perera T, George MS, Grammer G, et al. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3):336-346.

11. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. 2010 (updated 2022).

12. American Psychiatric Association Committee on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, 2nd Edition. 2001.

13. Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2022;179(2):132-141.

14. U.S. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (MDD), version 4.0. 2022.

15. UnitedHealthcare. Medical Policy 2023.09, Transcranial Magnetic Stimulation. Accessed via UHC provider portal, 2024.

16. Aetna. Clinical Policy Bulletin 0469, Transcranial Magnetic Stimulation. Last review 2023.

17. Cigna. Medical Coverage Policy 0104, Transcranial Magnetic Stimulation. Last review 2024.

18. Anthem (BCBS). Policy SURG.00132, Transcranial Magnetic Stimulation. Last review 2023.